Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Theravance (THRX) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 1,147,250
  • Shares Outstanding, K 117,430
  • Annual Sales, $ 8,430 K
  • Annual Income, $ -168,460 K
  • 36-Month Beta 1.79
  • Price/Sales 185.76
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.34
  • Most Recent Earnings -0.04 on 10/28/15
  • Annual Dividend & Yield 1.00 (10.23%)
  • Most Recent Dividend 0.25 on 09/08/15
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.24 +6.17%
on 12/11/15
11.19 -12.33%
on 12/29/15
+0.31 (+3.26%)
since 12/08/15
3-Month
7.80 +25.77%
on 10/13/15
11.19 -12.33%
on 12/29/15
+1.06 (+12.11%)
since 10/08/15
52-Week
6.36 +54.25%
on 09/29/15
21.16 -53.64%
on 03/09/15
-3.29 (-25.11%)
since 01/08/15

Most Recent Stories

More News
The 3 Most Important Numbers When GlaxoSmithKline Reports Its Fourth-Quarter Results

Image source: GlaxoSmithKline. Among Big Pharma, no drugmaker in particular has been given a reprieve from the patent cliff. However, U.K.-based GlaxoSmithKline was just late to the party. Whereas...

Theravance Inc. Stock Was Up 14% in December -- Here's Why

What : Shares of  Theravance Inc , a healthcare royalty company, put up another greatly monthly performance as the company's stock moved more than 14% higher during the month of December, according...

Theravance, Inc. Announces Name Change to Innoviva, Inc.

Theravance, Inc. (NASDAQ: THRX), a healthcare-focused asset management company, today announced that it changed its name to Innoviva, Inc., effective January 7, 2016. In addition to Innoviva's new name,...

Will 2016 Be GlaxoSmithKline plc's Best Year Yet?

Image source: GlaxoSmithKline. Although the broad-based market was relatively flat this year, some investors are certainly happy to put 2015 in the rearview mirror. Shareholders of U.K.-based pharma...

Theravance Up 17.4% Since SmarTrend Uptrend Call (THRX)

SmarTrend identified an Uptrend for Theravance (NASDAQ:THRX) on October 5th, 2015 at $9.09. In approximately 3 months, Theravance has returned 17.38% as of today's recent price of $10.67.

SmarTrend Watching for Potential Pullback in Shares of Theravance After 3.82% Gain

Theravance (NASDAQ:THRX) traded in a range yesterday that spanned from a low of $10.41 to a high of $10.91. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $10.75...

The Best GlaxoSmithKline plc Headlines in 2015

Image source: GlaxoSmithKline via Flickr. As the year comes to a close, the only certainty shareholders of U.K.-based pharmaceutical giant GlaxoSmithKline have known this year is constant uncertainty....

Theravance Shares Up 16.3% Since SmarTrend's Buy Recommendation (THRX)

SmarTrend identified an Uptrend for Theravance (NASDAQ:THRX) on October 5th, 2015 at $9.09. In approximately 3 months, Theravance has returned 16.28% as of today's recent price of $10.57.

Uptrend Call Working As Theravance Stock Rises 16.3% (THRX)

SmarTrend identified an Uptrend for Theravance (NASDAQ:THRX) on October 5th, 2015 at $9.09. In approximately 3 months, Theravance has returned 16.28% as of today's recent price of $10.57.

Will GlaxoSmithKline plc Raise Its Dividend in 2016?

Image source: GlaxoSmithKline.  It's been a rough 2015 for Big Pharma stocks, which have been whipsawed for much of the year, but the one solace that most large drug developers continue to offer their...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Theravance Inc is focused on the discovery, development and commercialization of small molecule medicines for unmet medical needs across a number of therapeutic areas including respiratory disease, bacterial infections, overactive bladder and gastrointestinal disorders.

See More

Support & Resistance

2nd Resistance Point 10.54
1st Resistance Point 10.18
Last Price 9.81
1st Support Level 9.52
2nd Support Level 9.22

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.